Investment Thesis
MapLight Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and minimal path to profitability in the near term. Operating losses of $169.1M against only $46.7M in cash reserves indicate the company is in critical funding distress and will require immediate capital raises or significant operational changes to avoid insolvency.
Strengths
- Strong balance sheet with $458.4M stockholders equity and zero long-term debt provides flexibility for capital restructuring
- Exceptional liquidity ratios (20.01x current and quick ratios) indicate no immediate short-term payment obligations
- Recent insider activity with 21 Form 4 filings in last 90 days suggests ongoing company developments
Risks
- No revenue generation indicates failed or non-existent commercialization of pipeline; company has not achieved clinical or commercial viability
- Annual operating cash burn of $138.1M with only $46.7M cash on hand means runway is critically short (approximately 4 months) without additional funding
- Net losses accelerating (-107.7% YoY change in net income) with diluted EPS of -$18.56 demonstrates worsening financial deterioration and shareholder value destruction
- Negative ROE of -35.2% and ROA of -33.6% confirm company is destroying shareholder capital at alarming rates
- Pre-revenue biotech model carries extreme binary risk with no evidence of successful product development or near-term revenue potential
Key Metrics to Watch
- Quarterly cash runway and burn rate trajectory - critical for survival assessment
- Evidence of clinical trial progress, regulatory approvals, or partnership announcements indicating revenue potential
- Capital raise activities and terms - dilution and pricing will signal investor confidence levels
- Operating expense reductions and path to profitability milestones
Financial Metrics
Revenue
N/A
Net Income
-161.2M
EPS (Diluted)
$-18.56
Free Cash Flow
-138.6M
Total Assets
479.5M
Cash
46.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-35.2%
ROA
-33.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
20.01x
Quick Ratio
20.01x
Debt/Equity
0.00x
Debt/Assets
4.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-02T05:12:11.408180 |
Data as of: 2025-12-31 |
Powered by Claude AI